|139.50||+13.81||+10.99%||Vol 16.19M||1Y Perf 2 780.21%|
|Nov 30th, 2020 16:00 DELAYED|
|-6.97 -5.55%||- -|
|Target Price||186.20||Analyst Rating||Strong Buy 1.50|
|Potential %||33.48||Finscreener Ranking||★★★+ — 53.09|
|Insiders Trans % 3/6/12 mo.||-100/-97/-95||Value Ranking||★★★ — 51.71|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 63.32|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-99/-98||Income Ranking||— -|
|Market Cap||8.88B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||73.14||Earnings Date||9th Nov 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|1 Year||2 780.21%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.36|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||8.13M|
|Avg. Monthly Volume||4.75M|
|Avg. Quarterly Volume||4.40M|
Novavax Inc. (NASDAQ: NVAX) stock closed at 139.5 per share at the end of the most recent trading day (a 10.99% change compared to the prior day closing price) with a volume of 16.38M shares and market capitalization of 8.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 168 people. Novavax Inc. CEO is Stanley Charles Erck.
The one-year performance of Novavax Inc. stock is 2780.21%, while year-to-date (YTD) performance is 3405.03%. NVAX stock has a five-year performance of -18.42%. Its 52-week range is between 3.65 and 189.4, which gives NVAX stock a 52-week price range ratio of 73.14%
Novavax Inc. currently has a PE ratio of -24.30, a price-to-book (PB) ratio of 75.17, a price-to-sale (PS) ratio of 31.90, a price to cashflow ratio of 97.10, a PEG ratio of 2.32, a ROA of -48.61%, a ROC of -38.46% and a ROE of 557.43%. The company’s profit margin is -%, its EBITDA margin is -124.70%, and its revenue ttm is $204.76 Million , which makes it $3.22 revenue per share.
Of the last four earnings reports from Novavax Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $2.36 for the next earnings report. Novavax Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Novavax Inc. is Strong Buy (1.5), with a target price of $186.2, which is +33.48% compared to the current price. The earnings rating for Novavax Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Novavax Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Novavax Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.05, ATR14 : 8.06, CCI20 : -69.97, Chaikin Money Flow : -0.21, MACD : -5.50, Money Flow Index : 59.02, ROC : -5.11, RSI : 42.77, STOCH (14,3) : 34.21, STOCH RSI : 0.59, UO : 41.67, Williams %R : -65.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Novavax Inc. in the last 12-months were: Gary C. Evans (Option Excercise at a value of $430 600), Gary C. Evans (Sold 21 000 shares of value $3 159 240 ), Gregory Glenn (Buy at a value of $4 825), Gregory Glenn (Option Excercise at a value of $0), Gregory M. Glenn (Buy at a value of $4 825), Gregory M. Glenn (Option Excercise at a value of $2 732 083), Gregory M. Glenn (Sold 117 619 shares of value $14 009 263 ), James F. Young (Buy at a value of $146 490), John A. Herrmann (Option Excercise at a value of $5 950 647), John A. Herrmann (Sold 203 964 shares of value $23 958 640 ), John J. Trizzino (Option Excercise at a value of $4 712 212), John J. Trizzino (Sold 176 718 shares of value $22 674 539 ), Michael A. Mcmanus (Option Excercise at a value of $220 800), Michael A. Mcmanus (Sold 16 000 shares of value $2 336 000 ), Stanley Charles Erck (Option Excercise at a value of $148 750), Stanley Charles Erck (Sold 38 445 shares of value $4 234 007 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.